Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASCO 2019

31 May - 4 Jun 2019
McCormick Place, Chicago, United States of America
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Comment: POLO III trial for metastatic pancreatic cancer
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Comment: POLO III trial for metastatic pancreatic cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
24 Jun 2019
Getting high level care to low and middle income countries
Dr Eduardo Cazap, Dr Clifford Hudis
Getting high level care to low and middle income countries ( Dr Eduardo Cazap, Dr Clifford Hudis )
21 Jun 2019
Tackling the increase in cancer cases worldwide
Dr Eduardo Cazap and Prof Tezer Kutluk
Tackling the increase in cancer cases worldwide ( Dr Eduardo Cazap and Prof Tezer Kutluk )
21 Jun 2019
How will ASCO combat cancer disparities?
Dr Eduardo Cazap, Dr Richard Schilsky
How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )
21 Jun 2019
PARP inhibitors olaparib and talazoparib as treatment for metastatic breast canc...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2019
Are PARP inhibitors a new standard of care option for MBC patients?
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with ot...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Dr Joel Neal - Stanford University, Stanford, USA
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )
18 Jun 2019
Comment: Enfortumab vedotin is an effective therapy and important development fo...
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )
18 Jun 2019
Cancer care in low and middle income countries
Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India
Cancer care in low and middle income countries ( Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India )
18 Jun 2019
Cancer care in Latin America
Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico
Cancer care in Latin America ( Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico )
18 Jun 2019
Surveying cancer patients' mental health and financial problems
Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa
Surveying cancer patients' mental health and financial problems ( Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa )
18 Jun 2019
Implementing better cancer diagnosis in low and middle income countries
Dr Gilberto Lopes - University of Miami and the Miller School of Medicine, Miami...
Implementing better cancer diagnosis in low and middle income countries ( Dr Gilberto Lopes - University of Miami and the Miller School of Medicine, Miami, USA )
18 Jun 2019
Project Pink Blue: Fighting cancer through increasing awareness, screening, advo...
Runcie C.W. Chidebe - Executive Director, Project PINK BLUE
Project Pink Blue: Fighting cancer through increasing awareness, screening, advocacy and patient navigation ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )
18 Jun 2019
Challenges in global cancer control
Prof Mary Gospodarowicz - University Health Network, Toronto, Canada
Challenges in global cancer control ( Prof Mary Gospodarowicz - University Health Network, Toronto, Canada )
18 Jun 2019
Novel methods of drug testing and biopsy in India
Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India
Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )
18 Jun 2019
Cutting-edge cancer care at the Miami Cancer Institute
Dr Miguel Villalona - Miami Cancer Institute, Miami, USA
Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )
18 Jun 2019
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced o...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
Comment: Chemotherapy for frail and elderly patients with advanced gastroesophag...
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019
Comment: Laparoscopic versus open resection for colorectal liver metastases
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Comment: Laparoscopic versus open resection for colorectal liver metastases ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019
CheckMate-142: Updated data from MSI high metastatic colon cancer patients
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-m...
Prof Hope Rugo - University of California, San Francisco, USA
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019
Advances in PARP inhibitor use for metastatic breast cancer
Prof Hope Rugo - University of California, San Francisco, USA
Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019
Margetuximab for the treatment of HER2-positive breast cancer
Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston,...
Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
12 Jun 2019
The future of PARP inhibitors in metastatic breast cancer
Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston,...
The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
12 Jun 2019
DORA: Using olaparib alone or with durvalumab in platinum responsive advanced tr...
Dr Tira Tan - National Cancer Centre, Singapore
DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )
12 Jun 2019
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients...
Dr Johannes Ettl - Technical University, Munich, Germany
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )
12 Jun 2019
ECHO palliative care in Africa: Improving access to quality palliative care
Runcie C.W. Chidebe - Executive Director, Project PINK BLUE
ECHO palliative care in Africa: Improving access to quality palliative care ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )
11 Jun 2019
Developments in neoadjuvant immunotherapy options for early-stage lung cancer pa...
Dr Luis Raez - Memorial Healthcare System, Hollywood, USA
Developments in neoadjuvant immunotherapy options for early-stage lung cancer patients ( Dr Luis Raez - Memorial Healthcare System, Hollywood, USA )
11 Jun 2019
Implementing the Breast Health Global Initiative guidelines
Prof Benjamin Anderson - Fred Hutchinson Cancer Center, Seattle, USA
Implementing the Breast Health Global Initiative guidelines ( Prof Benjamin Anderson - Fred Hutchinson Cancer Center, Seattle, USA )
11 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSC...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spai...
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Jun 2019
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Expanding clinical trial eligibility criteria: Risks and solutions
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Ribociclib plus endocrine therapy improves survival in premenopausal patients wi...
Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston,...
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Jun 2019
ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer
Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK
ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )
11 Jun 2019
ASCO 2019 and vision for cancer control
Dr Eduardo Cazap - Editor-in-Chief, ecancer
ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )
11 Jun 2019
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers...
Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial ( Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Jun 2019
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 m...
Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Guiding treatment decisions through the use of molecular profiling in breast can...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Managing metastatic breast cancer and beyond using PARP inhibitors
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Updates in metastatic and early-stage breast cancer
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
PARP inhibitors in metastatic breast cancer: Where are we now?
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus riboc...
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor ...
Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )
10 Jun 2019
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0...
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemo...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC...
Prof Hope Rugo - University of California, San Francisco, USA
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )
10 Jun 2019
Updates in the management of pancreatic cancer from ASCO 2019
Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai
Updates in the management of pancreatic cancer from ASCO 2019 ( Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai )
7 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )
7 Jun 2019
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patie...
Prof Max Topp - University of Würzburg, Würzburg, Germany
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
6 Jun 2019
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunothera...
Prof Max Topp - University of Würzburg, Würzburg, Germany
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
6 Jun 2019
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherap...
Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Sp...
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
6 Jun 2019
Breast cancer highlights from ASCO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression...
Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for loc...
Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )
6 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )
6 Jun 2019
FORTE trial results: KRd with or without transplantation in newly diagnosed myel...
Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turi...
FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status ( Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy )
6 Jun 2019
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast canc...
Dr Zahi Mitri - OHSU Hospital, Portland, USA
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )
6 Jun 2019
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
6 Jun 2019
ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in ...
Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA
ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas ( Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Jun 2019
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients wit...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )
6 Jun 2019
ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblasti...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
6 Jun 2019
Prostate cancer updates: TITAN and ENZAMET
Prof Ian Davis and Prof Axel Merseburger
Prostate cancer updates: TITAN and ENZAMET ( Prof Ian Davis and Prof Axel Merseburger )
3 Jun 2019
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019
Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019 ( Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger )
3 Jun 2019
Metastatic bladder cancer: Current practice and latest data from ASCO 2019
Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones
Metastatic bladder cancer: Current practice and latest data from ASCO 2019 ( Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones )
3 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Potential of PARP inhibitors for metastatic breast cancer
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
Preventing brain metastases in patients with HER2 or triple negative breast can...
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Preventing brain metastases in patients with HER2  or triple negative breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Long-term survival after laparoscopic versus open resection for colorectal liver...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
Long-term survival after laparoscopic versus open resection for colorectal liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
Targeting agent enfortumab vedotin a novel treatment for patients with advanced ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of patien...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
No difference in survival between laparoscopic surgery and open surgery in color...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
Novel therapies in the treatment of bladder cancer
Dr Petros Grivas and Dr Andrea Necchi
Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )
3 Jun 2019
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer wi...
Prof Arnaud Mejean - Paris Descartes University, Paris, France
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )
3 Jun 2019
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA ge...
Dr Hedy Kindler - University of Chicago, Chicago, USA
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )
2 Jun 2019
Enzalutamide as treatment for men with mHSPC who have received testosterone supp...
Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney -  Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2019
Enzalutamide improves survival for men with metastatic hormone-sensitive prostat...
Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney -  Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2019
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroi...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )
2 Jun 2019
Maintenance therapy with PARP inhibitor olaparib delays progression in patients ...
Dr Hedy Kindler - University of Chicago, Chicago, USA
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )
2 Jun 2019
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients...
Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )
2 Jun 2019
Improving cancer care outcomes in Ghana through mentorship
Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana
Improving cancer care outcomes in Ghana through mentorship ( Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana )
2 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage ...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, US...
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic...
Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )
1 Jun 2019
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitin...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
PARP inhibitors are a promising alternative to chemotherapy for patients with me...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition t...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
Subcutaneous versus intravenous daratumumab administration in patients with rela...
Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as tr...
Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junc...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spa...
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemothera...
Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or g...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Sp...
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we ...
Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall survival...
Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival ...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
Ribociclib and endocrine therapy improves survival for pre-menopausal women with...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019